Mangoceuticals acquires a global patent portfolio for preventative care

Mangoceuticals announces that it has acquired a global patent portfolio for a pioneering oral solution and application aimed to combat and prevent a spectrum of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus, HPV, from Intramont Technologies pursuant to a Patent Purchase Agreement, PPA. Jacob Cohen, Co-Founder and CEO of MangoRx commented, “We are thrilled to integrate this groundbreaking solution into our current portfolio of products, as this further signifies our entrance into non-prescription, or non-Rx, based products, which can be sold both via direct-to-consumer online or in retail locations. This acquisition aligns perfectly with our mission to enhance well-being through innovative health solutions. Through working to commercialize this technology, we aim to unlock significant value for our shareholders while advancing global health and addressing significant market needs.”